Peltekian KM

Idioma: Ingles.
Referencias bibliográficas: 13
Paginas: 710-712
Archivo PDF: 65.18 Kb.

FRAGMENTO

sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, et al. Prevalence of nonalcoholic Fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45.

2. Pérez-Gutiérrez OZ, Hernández-Rocha C, Candia-Balboa RA, Arrese MA, Benítez C, Brizuela-Alcántara DC, Méndez- Sánchez N, et al. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Ann Hepatol 2013; 12: 416-24.

3. Said A, Gagovic V, Malecki K, Givens ML, Nieto FJ. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann Hepatol 2013;12: 758-65.

4. Global Guidelines-Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, World Gastroenterology Organization (June 2012).

5. Polyzos SA, Kountouras J, Papatheodorou A, Katsiki E, Patsiaoura K, Zafeiriadou E, Zavos C, et al. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: introduction of CHA index. Ann Hepatol 2013; 12: 749-57.

6. Uribe M, Zamora-Valdés D, Moreno-Portillo M, Bermejo- Martínez L, Pichardo-Bahena R, Baptista-González HA, Ponciano-Rodríguez G, et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann Hepatol 2008; 7: 67-71.

7. de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003; 2(1): 5-11.

8. Vecchi VL, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, La Spada E, Vizzini G, et al. Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV-infected patients. Ann Hepatol 2013; 12: 740-48.

9. Barrera F, Riquelme A, Soza A, Contreras A, Barrios G, Padilla O, Viviani P, et al. Platelet count/spleen diameter ratio for non-invasive prediction of high risk esophageal varices in cirrhotic patients. Ann Hepatol 2009; 8: 325-30.

10. Li Vecchi V, Soresi M, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, Terranova A, et al. Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Int J Infect Dis 2012; 16: 397-402.

11. de Mattos AZ, de Mattos AA, Daros LF, Musskopf MI. Aspartate aminotransferase-to-platelet ratio index (APRI) for the non-invasive prediction of esophageal varices. Ann Hepatol 2013;12: 810-14.

12. Mattos AZ, Mattos AA, Vianna FF, Musskopf MI, Pereira- Lima JC, Maciel AC. Platelet count/spleen diameter ratio: analysis of its capacity as a predictor of the existence of esophageal varices. Arq Gastroenterol 2010; 47: 275-8.

13. Gaba RC, Shah KD, Couture PM, Parvinian A, Minocha J, Knuttinen MG, Bui JT. Within-patient temporal variance in MELD score and impact on survival prediction after TIPS creation. Ann Hepatol 2013; 12: 797-802.